GlassScriptPhysician profile
Sherrin Soliman
NPI 1740807619
$2,132.05
in general payments reported to CMS, 2019-2025
11 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $957 · 2022: $119 · 2023: $402 · 2024: $390 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.43 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $665.28 | 2021-2023 | Wegovy |
| Abbvie INC. | $520.85 | 2021-2024 | Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $240.12 | 2021-2024 | |
| Lilly USA, LLC | $153.89 | 2021-2024 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $151.72 | 2021 | |
| Heron Therapeutics, INC. | $121.84 | 2025 | Aponvie, Zynrelef |
| Nevro Corp. | $112.29 | 2021 | |
| Baxter Healthcare | $103.75 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.70 | 2025 | Jardiance |
| Radius Health, INC. | $12.32 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherrin Soliman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.